Laboratory Tests and Monitoring for Kesimpta (Ofatumumab) Therapy

Baseline Laboratory Tests

The American College of Physicians recommends tuberculosis screening with either Quantiferon TB Gold test or Tuberculin skin test (TST) for patients prior to initiating Kesimpta (ofatumumab) therapy, especially for those with prior TB exposure or from regions with high TB prevalence 1, 2
Baseline liver function tests, including AST/ALT, alkaline phosphatase, and bilirubin, are recommended to establish liver function prior to initiating therapy that may affect the liver 1
Renal function tests, including blood urea nitrogen (BUN), serum creatinine, and estimated glomerular filtration rate (eGFR), are recommended to assess baseline kidney function 1
A pregnancy test is recommended for women of childbearing potential before starting Kesimpta (ofatumumab) therapy 1

Serum electrolytes, including sodium, potassium, calcium, and magnesium, should be established as baseline values 1
A vaccination status review is recommended, and patients should receive any needed vaccinations, particularly live vaccines, prior to starting ofatumumab, as B-cell depleting therapy may reduce vaccine effectiveness 3